pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
292
stories
13h
Contrasting legal decisions on gender-affirming care
stat
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
stat
1d
Enveda’s exercise-simulating obesity tablet clears early clinical test
biospace
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
1d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
2d
Leo Pharma buys rare skin disease drug in $435M deal
biopharma dive
2d
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
2d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
2d
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
fiercebiotech
2d
Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure
endpoints
3d
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
fiercebiotech
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
7d
STAT+: Eli Lilly targets booming black market for retatrutide
stat
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
7d
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
stat
7d
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
endpoints
7d
Behind the bell: Gearing up to go public
biospace
7d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
8d
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
biospace
8d
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
8d
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
biospace
8d
Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials
endpoints
8d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
fiercebiotech
← prev
page 1 of 10
next →
